Bionomics names new chairman
18 October, 2004 by Renate KrelleBionomics (ASX:BNO) has appointed former Reserve Bank economist Dr Peter Jonson as chairman, and extended the contract of chief executive officer and managing director Dr Deborah Rathjen until June 2008.
New player Gateway aims to fill commercialisation gap
15 October, 2004 by Renate KrellePerth-based biotech project management company Gateway Capital is about to step into the ring with venture capital players and investment banks, announcing today it will aim to fast-track biotech research from research institute to ASX.
Agenix sets up deal with US firm Inverness
15 October, 2004 by Melissa TrudingerAgenix (ASX:AGX) subsidiary AGEN Biomedical has secured a manufacturing and technology transfer alliance with US company Inverness Medical Innovations for its animal health diagnostic products.
Cytopia to raise $13m in rights issue
13 October, 2004 by Melissa TrudingerCytopia (ASX:CYT) will raise AUD$13.2 million in a fully underwritten non-renounceable rights issue.
Tissue Therapies bolsters cash reserves
13 October, 2004 by Melissa TrudingerBrisbane company Tissue Therapies (ASX:TIS) has bolstered its cash reserves through a placement of $1.46 million before costs to institutional and sophisticated investors.
Living Cell tops up coffers with $4.8 million
13 October, 2004 by Renate KrelleAfter raising AUD$6.36 million in its IPO last month, Living Cell Technologies (ASX:LCT) has announced a successful AUD$4.8 million top-up of its cash reserves.
AusBiotech signs agreement with Indian counterpart
13 October, 2004 by Iain ScottBiotechnology industry association AusBiotech has signed a memorandum of understanding with its Indian counterpart, the Association of Biotechnology Led Enterprises (ABLE).
Prima subsidiary signs licence deal with AstraZeneca
12 October, 2004 by Renate KrelleHelmed by a new chairman and in the middle a AUD$5-10 million capital raising, Melbourne's Prima Biomed (ASX:PRR) has ticked the first of the boxes on its lengthy to-do list, announcing that its Arthron subsidiary has signed a non-exclusive license with AstraZeneca to validate its anti-inflammatory Fc receptor target.
Qualified success in Imugene trial
12 October, 2004 by Renate KrelleImugene (ASX:IMU) has claimed a qualified success after a trial to test the ability of its receptor mimic technology (RMT) to prevent post-weaning diarrhoea in piglets.
Benitec grants licence to US xeno firm Revivicor
12 October, 2004 by Graeme O'NeillBenitec (ASX:BLT) has granted a licence to US company Revivicor to use its patented RNAi-mediated gene-silencing technology for mammalian cells to develop transgenic pigs as a source of organ transplants for humans.
Peplin slumps as Allergan collaboration ends
11 October, 2004 by Melissa TrudingerPeplin's share price has dropped 30 per cent today (Monday) on heavy trading after the company announced late on Friday that its collaboration with Allergan was to be discontinued, and all rights for the development and commercialisation of the company's topical skin cancer drug, PEP005 Topical, as well as data and IP generated during the collaboration, are to be returned to the Brisbane-based company.
In brief: Sirtex, GTG, LCT, Bone
11 October, 2004 by Melissa TrudingerIndependent clinical studies performed in the US, Europe and Australia have verified the efficacy of Sirtex Medical's (ASX:SRX) SIR-Spheres liver cancer treatment.
Anti-GM movement knew of 'secret' trials
11 October, 2004 by Graeme O'NeillClaims by anti-GM activists that the Victorian government and Bayer CropScience are putting farmers' livelihoods at risk, by keeping secret the locations of genetically modified canola trials, have been scotched with the revelation that they have known the location of at least one participating farm for more than a year.
Early results bode well for Psivida's biosilicon
07 October, 2004 by Graeme O'NeillThe first four patients with inoperable liver cancer involved in a Phase IIa clinical trial of an in situ radiotherapy treatment developed by Perth nano-biotech company Psivida (ASX:PSD) have experienced regressions of up to 60 per cent in their tumours.
Chemeq shares jump as first order shipped
06 October, 2004 by Melissa TrudingerChemeq shares jumped 46 per cent today after the company announced that it had shipped its first order of its polymeric anti-microbial product to South Africa for use in poultry.
